According to FDA Draft Guidance for Industry in Electronic Submission and Study Data Technical Conformance Guide, the pharmaceutical companies will need to provide CDISC Electronic submission to FDA. The paper will explain Data Standard Catalog which will dictate FDA Standards. The paper will discuss how to prepare CDISC electronic submission and what to prepare in CDISC electronic submission.
Confused by FDA Guidance on Standardized Study Data for Electronic Submissions?Brook White, PMP
In December 2014, FDA released the finalized Guidance for Industry “Providing Regulatory Submissions in Electronic Format—Standardized Study Data.” This presentation reviews key points in the guidance and discusses the implications for Sponsors currently conducting studies as well as those who will be starting new studies soon.
The document discusses standards for clinical trial data submission, including:
- Regulatory agencies are pushing for standardized data submission to improve review efficiency under PDUFA. CDISC standards including SDTM and ADaM are becoming required.
- CDISC regularly updates and expands clinical data standards to include new domains and enhancements.
- A properly constructed define.xml file documenting the metadata is important for reviewers to understand the data.
INTERPRETING CDISC ADaM IG THROUGH USERS INTERPRETATIONAngelo Tinazzi
The document appears to be a presentation about interpreting the CDISC ADaM Implementation Guide. It discusses conducting a systematic review of papers discussing ADaM implementation to understand areas of ambiguity and different interpretations. The review found over 100 papers focused on ADaM implementation, with the most discussions at PharmaSUG and PhUSE conferences. Common topics of interpretation included traceability, non-ADaM analysis datasets, validation, and issues with the basic data structure. The presentation aims to facilitate discussion on resolving areas of ambiguity in the guide.
Beyond regulatory submission - standards metadata managementKevin Lee
After FDA published the final “Guidance for Industry on electronic submission” that will require submission data in CDISC standards, all the life sciences organizations focus on implementing CDISC standards on clinical data development. However, organizations also see other opportunities with CDISC standards. The presentation will introduce what could be possible through Standards such as Standards-driven automated process in clinical artefacts development and how the organization need to manage and govern standards in order to achieve the next steps.
Over the past decade, CDISC Standards have been widely accepted and implemented in clinical research. The FDA’s final “Guidance for Industry on electronic submission” mandates that submission data conform to CDISC standards such as SDTM, ADaM and SEND. This presentation will discuss how life sciences organizations can use Standards metadata to manage the regulatory compliance process. It will introduce how standards metadata management not only ensures regulatory compliance, but also supports process efficiency in clinical trial artefacts (e.g., protocol, CDASH, SDMT and ADaM) development and standards governance, and enables efficient communication between organizational units.
It will also introduce metadata management system and discuss how metadata management system will create, store, govern and manage standards. It will also show how standards metadata management system interacts with ETL system and dictates standards-driven clinical artefacts development.
This document discusses ADaM metadata, which provides information about Analysis Data Model (ADaM) datasets. It presents examples of metadata for time to event analyses, including analysis dataset, variable, parameter value-level, and results metadata. The goal of metadata is to specify how to create ADaM and TFL datasets, define information for sponsors, and promote consistency between sites. Benefits include reduced communication needs, easier estimation and planning, and help for inexperienced users. Challenges include initial time/resource investment and determining who maintains the metadata.
This document describes a presentation by Angelo Tinazzi of Cytel Inc. looking for an SDTM specialist to work at the PhUSE conference in London from October 12-15, 2014. It provides examples of challenges faced in legacy data conversion, including a case study of performing a gap analysis for a small biotech company and discussing issues in modeling oncology study data to SDTM.
According to FDA Draft Guidance for Industry in Electronic Submission and Study Data Technical Conformance Guide, the pharmaceutical companies will need to provide CDISC Electronic submission to FDA. The paper will explain Data Standard Catalog which will dictate FDA Standards. The paper will discuss how to prepare CDISC electronic submission and what to prepare in CDISC electronic submission.
Confused by FDA Guidance on Standardized Study Data for Electronic Submissions?Brook White, PMP
In December 2014, FDA released the finalized Guidance for Industry “Providing Regulatory Submissions in Electronic Format—Standardized Study Data.” This presentation reviews key points in the guidance and discusses the implications for Sponsors currently conducting studies as well as those who will be starting new studies soon.
The document discusses standards for clinical trial data submission, including:
- Regulatory agencies are pushing for standardized data submission to improve review efficiency under PDUFA. CDISC standards including SDTM and ADaM are becoming required.
- CDISC regularly updates and expands clinical data standards to include new domains and enhancements.
- A properly constructed define.xml file documenting the metadata is important for reviewers to understand the data.
INTERPRETING CDISC ADaM IG THROUGH USERS INTERPRETATIONAngelo Tinazzi
The document appears to be a presentation about interpreting the CDISC ADaM Implementation Guide. It discusses conducting a systematic review of papers discussing ADaM implementation to understand areas of ambiguity and different interpretations. The review found over 100 papers focused on ADaM implementation, with the most discussions at PharmaSUG and PhUSE conferences. Common topics of interpretation included traceability, non-ADaM analysis datasets, validation, and issues with the basic data structure. The presentation aims to facilitate discussion on resolving areas of ambiguity in the guide.
Beyond regulatory submission - standards metadata managementKevin Lee
After FDA published the final “Guidance for Industry on electronic submission” that will require submission data in CDISC standards, all the life sciences organizations focus on implementing CDISC standards on clinical data development. However, organizations also see other opportunities with CDISC standards. The presentation will introduce what could be possible through Standards such as Standards-driven automated process in clinical artefacts development and how the organization need to manage and govern standards in order to achieve the next steps.
Over the past decade, CDISC Standards have been widely accepted and implemented in clinical research. The FDA’s final “Guidance for Industry on electronic submission” mandates that submission data conform to CDISC standards such as SDTM, ADaM and SEND. This presentation will discuss how life sciences organizations can use Standards metadata to manage the regulatory compliance process. It will introduce how standards metadata management not only ensures regulatory compliance, but also supports process efficiency in clinical trial artefacts (e.g., protocol, CDASH, SDMT and ADaM) development and standards governance, and enables efficient communication between organizational units.
It will also introduce metadata management system and discuss how metadata management system will create, store, govern and manage standards. It will also show how standards metadata management system interacts with ETL system and dictates standards-driven clinical artefacts development.
This document discusses ADaM metadata, which provides information about Analysis Data Model (ADaM) datasets. It presents examples of metadata for time to event analyses, including analysis dataset, variable, parameter value-level, and results metadata. The goal of metadata is to specify how to create ADaM and TFL datasets, define information for sponsors, and promote consistency between sites. Benefits include reduced communication needs, easier estimation and planning, and help for inexperienced users. Challenges include initial time/resource investment and determining who maintains the metadata.
This document describes a presentation by Angelo Tinazzi of Cytel Inc. looking for an SDTM specialist to work at the PhUSE conference in London from October 12-15, 2014. It provides examples of challenges faced in legacy data conversion, including a case study of performing a gap analysis for a small biotech company and discussing issues in modeling oncology study data to SDTM.
Metadata becomes alive via a web service between MDR and SASKevin Lee
The life science organizations use Metadata Repository (MDR) to manage and govern metadata, which could be used for artifacts generation such as SDTM, ADaM and TFL. In order to develop artifacts, metadata in MDR needs to be assessed by analytic systems such as SAS. The presentation will show how MDR and SAS could exchange metadata over internet. The presentation will introduce the basic concepts of a web service and Simple Object Access protocol (SOAP). It will show how SAS can receive metadata from MDR using SOAP over internet and convert SOAP XML response file to SAS datasets. It will introduce SOAP XML request/response file, SOAPWEB and XMLMAP function.
Standards metadata management - version control and its governanceKevin Lee
Over the past decade, CDISC Standards have been widely accepted and implemented in clinical research. The FDA’s final “Guidance for Industry on electronic submission” mandates that submission data conform to CDISC standards, including SDTM, ADaM and SEND. Life sciences organizations, therefore, need to ensure that submission data be compliant to regulatory requirement standards (e.g., CDISC and eCTD). One of the biggest challenges, however, that organizations face is the evolution of standards, which lead the different versions of standards. The presentation will discuss how organization manage the different versions of industry standards and company standards. The presentation will introduce governance on metadata management.
Standards governance simply means “Do the right things” in standards implementation and management. The presentation will discuss how life sciences organizations can better fulfill their goals for standards implementation and management using governance. The presentation will also discuss the main aspects of data governance from the CDISC standards perspective, addressing the role of people(e.g., requestor, developer and approval), processes(e.g., work flow of requesting, developing and approving), and technology (e.g., spreadsheet, share point and MDR).
This document provides an overview and lessons learned from a presentation on electronic regulatory submissions (ERS) given by Adair Turner. It discusses the many changes that have occurred in ERS in recent years, including requirements for submissions over 10GB to use the Electronic Submissions Gateway and for studies to use CDISC formats. Major lessons highlighted include understanding eCTD fundamentals, allocating enough time, and trusting experts. Tips are provided on training resources, ESG setup, attributes, referencing previous submissions, PDF errors, datasets, and submission timelines.
After 10 years of eCTD the standard is fit for rejuvenation. Although eCTD has brought many benefits there is still significant room for improvement. This presentation covers different areas: continuous challenges associated with eCTD, Regulatory guidelines and eCTD viewing
Baseline submissions provide a single eCTD submission that captures all information reflecting previously submitted and approved marketing licenses for a drug. This consolidates multiple past eCTD submissions per strength into a single eCTD lifecycle. Benefits include removing redundant information, improving organization, and enabling reuse of documents across products. However, baseline submissions are time-consuming to create and can expose gaps or outdated information that was acceptable in past submissions but may not meet current requirements.
The Science of Submissions Part IB - How to handle grouping and worksharing i...eCTDconsultancy
The document discusses how to handle grouping and worksharing in eCTD submissions. It outlines changes to the eCTD specification related to variations, and the challenges this poses for business processes and dossier compilation across multiple products. Practical experience with lifecycle complexities, cover letter authorizations, and preparation timelines for grouped/workshared submissions is also examined.
Introduction to Oracle Clinical Overview in Clinical Data Management in Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Design Considerations to Maximize Medical Device Cloud ConnectivityGreenlight Guru
Medical device manufacturers are faced with a myriad of design decisions during product development. Several key decisions affecting market readiness must be addressed between bench-top prototypes and initiation of clinical trials. Among the most important are cloud connectivity considerations surrounding firmware, hardware, and use cases. The earlier cloud connectivity factors are identified, considered, and integrated into the design process, the more successful the resulting commercial roll-out in terms of cost, certification, and market acceptance.
• Key design factors medical device manufacturers should consider
• Advantages of considering connectivity early in the design process
• Practical use-case examples highlight more cost-effective clinical trials, wider market acceptance, and reduction in operational costs
This session took place live at the Greenlight Guru True Quality Virtual Summit, a three-day event for medical device professionals to learn to get their devices to market faster, stay ahead of regulatory changes, and use quality as their multiplier to grow their device business.
How to Prepare for and Make the Most Out of your FDA Pre-Submission: Leverage...Greenlight Guru
The FDA Pre-Submission process is one the most effective tools out there to de-risk your 510(k) yet it is often both under-utilized and used improperly.
The Pre-Sub allows for device manufacture to discuss and get feedback directly from FDA on both their product development and regulatory strategy.
When used properly the Pre-Sub process can result in significant time savings to market - however when used improperly or ignored all together, this can easily result in unnecessary delays and wasted money.
This presentation covers:
- What is a Pre-Sub and why it is so important
- How to prepare and get the most out of your Pre-Sub
- The exact Pre-Sub timeline of events
- An example of the contents to include and how to format your Pre-Sub
- What you should do after your Pre-Sub
- A step-by-step case study example of the Pre-Sub process
Watch the presentation with commentary here: https://www.greenlight.guru/webinar/fda-pre-submission-process
The document discusses the key activities involved in clinical study setup for data management, including designing case report forms (CRFs), developing the study database, programming validation and derivation procedures, and conducting user acceptance testing (UAT). It provides an overview of the study setup process and outlines the objectives, requirements, responsibilities, and deliverables for each setup activity.
This document provides an overview of key considerations for preparing Investigational New Drug (IND) and Clinical Trial Authorization (CTA) submissions to regulatory agencies. It discusses essential pre-submission planning steps like defining roles and timelines. It also reviews the structure and content of IND and CTA applications, highlighting similarities and differences between FDA, EMA, MHRA, and Health Canada requirements. The document emphasizes strategies for improving efficiency in multi-country submissions, such as reusing common documents and templates across applications.
AllTrials AAAS 2015 - Opportunities and Challenges for ClinicalTrials.govSenseAboutSci
This document discusses transparency and reporting of clinical trial results on ClinicalTrials.gov. It notes that not all trials are published, published reports do not always include all pre-specified outcomes, and unacknowledged changes are sometimes made to trial protocols. It summarizes key challenges with ClinicalTrials.gov compliance and reporting quality. The document also outlines proposed rules and policies to improve registration of trials and reporting of results on ClinicalTrials.gov in order to increase transparency and integrity of clinical research.
The document outlines a framework for developing and implementing data standards for drug regulatory reviewers at the FDA. It describes challenges with inconsistent, unpredictable, and paper-based regulatory submissions. It then summarizes the benefits of the framework, which include enhanced data quality and consistency, improved timeliness of review, and increased effectiveness of review. The framework establishes governance processes and applies project management discipline and processes to standardize how data standard projects are initiated, developed, tested, adopted and implemented.
Study setup_Clinical Data Management_Katalyst HLSKatalyst HLS
Introduction to Study Setup in Clinical Data Management in Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
A data management plan (DMP) ensures consistent and effective clinical data management practices throughout a clinical trial. The DMP describes all data management activities, responsibilities, and deliverables to promote agreement among parties. It not only describes the data management process, but also provides documentation of data handling for regulatory compliance. The DMP components include data flow, capture, setup, entry, transfer, processing, coding, safety data, external data, database locking and unlocking, archiving, and quality reports. It serves to plan, communicate, and reference all data management tasks during a study.
Clinical Data Management Plan_Katalyst HLSKatalyst HLS
A data management plan (DMP) ensures consistent and effective clinical data management practices throughout a clinical trial. The DMP describes all data management activities, roles, and responsibilities to promote standardized data handling. It provides an agreement between parties on data management deliverables. The DMP covers components like data flow, capture, setup, entry, transfer, processing, coding, safety handling, external data, and database locking. It serves to plan, communicate, and reference data management tasks. Developing a thorough DMP helps ensure quality and regulatory compliance in data collection and analysis.
NDA Submission Experience - Rescue Case StudyBhavin Busa
As a niche provider, Vita Data Sciences has handled several Sponsor rescue case studies since our inception. In this slide share (presented at PhUSE SDE in Boston), we aim to provide background of our NDA submission experience and present a rescue case study where our team worked with a Sponsor towards their final NDA submission packet, even though the Sponsor had outsourced these services to a global full-service CRO. We have provided a brief background and outline significant gaps identified in the deliverables, services we offered, and summarize lessons learned/recommendations which can come in handy for anyone who is starting to work on their NDA clinical datasets package. Your feedback and comments are welcome.
Recent and upcoming regulatory changes-TGARazia Zahid
The document summarizes recent and upcoming regulatory changes by the Therapeutic Goods Administration (TGA) in Australia, including the designation of conformity assessment bodies, accelerated assessment for novel devices, use of approvals from comparable overseas regulators, and continued harmonization with the European Union. Key points covered are the criteria and processes for designation of conformity assessment bodies, priority review for devices that address unmet clinical needs or provide major benefits, and acceptance of certificates and approvals from regulators like the EU, FDA, Health Canada, and Japan. The TGA is also aligning more closely with new European regulations and publishing additional guidance documents.
Presentation: Medical Devices Single Audit Program (MDSAP) Pilot ProgramTGA Australia
This presentation provides an update on the progress of the Pilot and explores how the results of audits will be used by the participating Regulatory Authorities in support of market authorisation within their jurisdictions.
Insights and Trends from 2021 FDA GCP Inspections.pptxMMS Holdings
The document summarizes insights and trends from the FDA's 2021 GCP inspections. It provides an overview of total inspections, top 483 observations for drugs and devices, and warning letters. Key findings include COVID-19 reducing inspections and alternative tools being used, top drug and device 483 observations relating to documentation and procedures, and most warning letters issued in March and October relating to drugs. It also discusses anticipated changes from the draft ICH E6(R3) guideline and trends for 2022, such as a potential increase in enforcement and focus on data security, quality controls, and corrective actions.
Metadata becomes alive via a web service between MDR and SASKevin Lee
The life science organizations use Metadata Repository (MDR) to manage and govern metadata, which could be used for artifacts generation such as SDTM, ADaM and TFL. In order to develop artifacts, metadata in MDR needs to be assessed by analytic systems such as SAS. The presentation will show how MDR and SAS could exchange metadata over internet. The presentation will introduce the basic concepts of a web service and Simple Object Access protocol (SOAP). It will show how SAS can receive metadata from MDR using SOAP over internet and convert SOAP XML response file to SAS datasets. It will introduce SOAP XML request/response file, SOAPWEB and XMLMAP function.
Standards metadata management - version control and its governanceKevin Lee
Over the past decade, CDISC Standards have been widely accepted and implemented in clinical research. The FDA’s final “Guidance for Industry on electronic submission” mandates that submission data conform to CDISC standards, including SDTM, ADaM and SEND. Life sciences organizations, therefore, need to ensure that submission data be compliant to regulatory requirement standards (e.g., CDISC and eCTD). One of the biggest challenges, however, that organizations face is the evolution of standards, which lead the different versions of standards. The presentation will discuss how organization manage the different versions of industry standards and company standards. The presentation will introduce governance on metadata management.
Standards governance simply means “Do the right things” in standards implementation and management. The presentation will discuss how life sciences organizations can better fulfill their goals for standards implementation and management using governance. The presentation will also discuss the main aspects of data governance from the CDISC standards perspective, addressing the role of people(e.g., requestor, developer and approval), processes(e.g., work flow of requesting, developing and approving), and technology (e.g., spreadsheet, share point and MDR).
This document provides an overview and lessons learned from a presentation on electronic regulatory submissions (ERS) given by Adair Turner. It discusses the many changes that have occurred in ERS in recent years, including requirements for submissions over 10GB to use the Electronic Submissions Gateway and for studies to use CDISC formats. Major lessons highlighted include understanding eCTD fundamentals, allocating enough time, and trusting experts. Tips are provided on training resources, ESG setup, attributes, referencing previous submissions, PDF errors, datasets, and submission timelines.
After 10 years of eCTD the standard is fit for rejuvenation. Although eCTD has brought many benefits there is still significant room for improvement. This presentation covers different areas: continuous challenges associated with eCTD, Regulatory guidelines and eCTD viewing
Baseline submissions provide a single eCTD submission that captures all information reflecting previously submitted and approved marketing licenses for a drug. This consolidates multiple past eCTD submissions per strength into a single eCTD lifecycle. Benefits include removing redundant information, improving organization, and enabling reuse of documents across products. However, baseline submissions are time-consuming to create and can expose gaps or outdated information that was acceptable in past submissions but may not meet current requirements.
The Science of Submissions Part IB - How to handle grouping and worksharing i...eCTDconsultancy
The document discusses how to handle grouping and worksharing in eCTD submissions. It outlines changes to the eCTD specification related to variations, and the challenges this poses for business processes and dossier compilation across multiple products. Practical experience with lifecycle complexities, cover letter authorizations, and preparation timelines for grouped/workshared submissions is also examined.
Introduction to Oracle Clinical Overview in Clinical Data Management in Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Design Considerations to Maximize Medical Device Cloud ConnectivityGreenlight Guru
Medical device manufacturers are faced with a myriad of design decisions during product development. Several key decisions affecting market readiness must be addressed between bench-top prototypes and initiation of clinical trials. Among the most important are cloud connectivity considerations surrounding firmware, hardware, and use cases. The earlier cloud connectivity factors are identified, considered, and integrated into the design process, the more successful the resulting commercial roll-out in terms of cost, certification, and market acceptance.
• Key design factors medical device manufacturers should consider
• Advantages of considering connectivity early in the design process
• Practical use-case examples highlight more cost-effective clinical trials, wider market acceptance, and reduction in operational costs
This session took place live at the Greenlight Guru True Quality Virtual Summit, a three-day event for medical device professionals to learn to get their devices to market faster, stay ahead of regulatory changes, and use quality as their multiplier to grow their device business.
How to Prepare for and Make the Most Out of your FDA Pre-Submission: Leverage...Greenlight Guru
The FDA Pre-Submission process is one the most effective tools out there to de-risk your 510(k) yet it is often both under-utilized and used improperly.
The Pre-Sub allows for device manufacture to discuss and get feedback directly from FDA on both their product development and regulatory strategy.
When used properly the Pre-Sub process can result in significant time savings to market - however when used improperly or ignored all together, this can easily result in unnecessary delays and wasted money.
This presentation covers:
- What is a Pre-Sub and why it is so important
- How to prepare and get the most out of your Pre-Sub
- The exact Pre-Sub timeline of events
- An example of the contents to include and how to format your Pre-Sub
- What you should do after your Pre-Sub
- A step-by-step case study example of the Pre-Sub process
Watch the presentation with commentary here: https://www.greenlight.guru/webinar/fda-pre-submission-process
The document discusses the key activities involved in clinical study setup for data management, including designing case report forms (CRFs), developing the study database, programming validation and derivation procedures, and conducting user acceptance testing (UAT). It provides an overview of the study setup process and outlines the objectives, requirements, responsibilities, and deliverables for each setup activity.
This document provides an overview of key considerations for preparing Investigational New Drug (IND) and Clinical Trial Authorization (CTA) submissions to regulatory agencies. It discusses essential pre-submission planning steps like defining roles and timelines. It also reviews the structure and content of IND and CTA applications, highlighting similarities and differences between FDA, EMA, MHRA, and Health Canada requirements. The document emphasizes strategies for improving efficiency in multi-country submissions, such as reusing common documents and templates across applications.
AllTrials AAAS 2015 - Opportunities and Challenges for ClinicalTrials.govSenseAboutSci
This document discusses transparency and reporting of clinical trial results on ClinicalTrials.gov. It notes that not all trials are published, published reports do not always include all pre-specified outcomes, and unacknowledged changes are sometimes made to trial protocols. It summarizes key challenges with ClinicalTrials.gov compliance and reporting quality. The document also outlines proposed rules and policies to improve registration of trials and reporting of results on ClinicalTrials.gov in order to increase transparency and integrity of clinical research.
The document outlines a framework for developing and implementing data standards for drug regulatory reviewers at the FDA. It describes challenges with inconsistent, unpredictable, and paper-based regulatory submissions. It then summarizes the benefits of the framework, which include enhanced data quality and consistency, improved timeliness of review, and increased effectiveness of review. The framework establishes governance processes and applies project management discipline and processes to standardize how data standard projects are initiated, developed, tested, adopted and implemented.
Study setup_Clinical Data Management_Katalyst HLSKatalyst HLS
Introduction to Study Setup in Clinical Data Management in Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
A data management plan (DMP) ensures consistent and effective clinical data management practices throughout a clinical trial. The DMP describes all data management activities, responsibilities, and deliverables to promote agreement among parties. It not only describes the data management process, but also provides documentation of data handling for regulatory compliance. The DMP components include data flow, capture, setup, entry, transfer, processing, coding, safety data, external data, database locking and unlocking, archiving, and quality reports. It serves to plan, communicate, and reference all data management tasks during a study.
Clinical Data Management Plan_Katalyst HLSKatalyst HLS
A data management plan (DMP) ensures consistent and effective clinical data management practices throughout a clinical trial. The DMP describes all data management activities, roles, and responsibilities to promote standardized data handling. It provides an agreement between parties on data management deliverables. The DMP covers components like data flow, capture, setup, entry, transfer, processing, coding, safety handling, external data, and database locking. It serves to plan, communicate, and reference data management tasks. Developing a thorough DMP helps ensure quality and regulatory compliance in data collection and analysis.
NDA Submission Experience - Rescue Case StudyBhavin Busa
As a niche provider, Vita Data Sciences has handled several Sponsor rescue case studies since our inception. In this slide share (presented at PhUSE SDE in Boston), we aim to provide background of our NDA submission experience and present a rescue case study where our team worked with a Sponsor towards their final NDA submission packet, even though the Sponsor had outsourced these services to a global full-service CRO. We have provided a brief background and outline significant gaps identified in the deliverables, services we offered, and summarize lessons learned/recommendations which can come in handy for anyone who is starting to work on their NDA clinical datasets package. Your feedback and comments are welcome.
Recent and upcoming regulatory changes-TGARazia Zahid
The document summarizes recent and upcoming regulatory changes by the Therapeutic Goods Administration (TGA) in Australia, including the designation of conformity assessment bodies, accelerated assessment for novel devices, use of approvals from comparable overseas regulators, and continued harmonization with the European Union. Key points covered are the criteria and processes for designation of conformity assessment bodies, priority review for devices that address unmet clinical needs or provide major benefits, and acceptance of certificates and approvals from regulators like the EU, FDA, Health Canada, and Japan. The TGA is also aligning more closely with new European regulations and publishing additional guidance documents.
Presentation: Medical Devices Single Audit Program (MDSAP) Pilot ProgramTGA Australia
This presentation provides an update on the progress of the Pilot and explores how the results of audits will be used by the participating Regulatory Authorities in support of market authorisation within their jurisdictions.
Insights and Trends from 2021 FDA GCP Inspections.pptxMMS Holdings
The document summarizes insights and trends from the FDA's 2021 GCP inspections. It provides an overview of total inspections, top 483 observations for drugs and devices, and warning letters. Key findings include COVID-19 reducing inspections and alternative tools being used, top drug and device 483 observations relating to documentation and procedures, and most warning letters issued in March and October relating to drugs. It also discusses anticipated changes from the draft ICH E6(R3) guideline and trends for 2022, such as a potential increase in enforcement and focus on data security, quality controls, and corrective actions.
Guidelines to the Preparation of document.pptxShraddhaRaut43
This presentation will give you insight of the Guidelines for preparation of Clinical Document such as Protocol, Investigator Brochure and Case Report Form. This will help you to learn deeply about the Clinical documentation.
The document discusses CDISC standards and their implementation. It begins by asking what the CDISC standards are, when is the best time to implement them, and the timeline for requiring them in FDA submissions. It then explains that CDISC develops data standards for medical research through an open consensus process. Implementing standards early in a clinical program saves time and money compared to converting legacy data later. The FDA will require CDISC standards like SDTM and ADaM for submissions through binding guidance issued in 2012 as part of critical path initiatives and legislative acts. Resources are available to stay up to date on standards development.
The document discusses open access policies for research data at the World Agroforestry Centre (ICRAF). It provides an overview of ICRAF's policy which states that data should be made openly accessible within 12 months of collection or project milestone. The policy allows centers flexibility to determine what constitutes incomplete or low-value data. Common misconceptions about open access are addressed, and benefits of open data are discussed such as improved publications, transparency, and recognition for researchers. Guidelines are provided for implementing open data policies including using metadata standards and archiving data.
NSF Data Requirements and Changing Federal Requirements for ResearchMargaret Henderson
This document discusses NSF requirements for data management plans and sharing research data. It provides an overview of what NSF expects to be included in a data management plan, such as the types of data produced, data standards, storage and preservation plans, policies for access and sharing, and archiving data for long-term access. The document also mentions other funder and government policies regarding public access to published research and supporting data. Resources for creating data management plans and sharing data, such as the DMPTool and research data repositories, are also introduced.
The document outlines the key steps in a clinical trial process, including study planning, implementation, analysis, and conclusion. As part of study planning, a protocol is developed, an informed consent form and case report forms are finalized, and a database is designed. Sites are then selected and approved by an ethics committee. For implementation, sites are activated, patients are screened and enrolled if eligible, and data is collected and entered into case report forms. The data is then validated, cleaned, and locked for analysis. Statistical analysis is conducted according to a pre-specified plan and results are submitted to regulators. In conclusion, clinical trials require careful planning and implementation to generate accurate data and unambiguous conclusions about test treatments.
This document discusses developing analytical evaluation standards for next generation sequencing (NGS) diagnostic tests. It outlines the FDA's vision of implementing standards and shared resources to enable research and provide accurate NGS test results for patients. The document discusses developing performance standard elements, areas needing standards, the overall NGS test workflow, and existing guidelines. It also discusses stakeholder groups involved in standard development and a proposed bioinformatics tools repository to help developers meet standards. The success of precision medicine will require accurate and safe NGS diagnostic tests within a learning healthcare system.
Is your product or medical device FDA-friendly? Learn about how to get a safe and effective product into the market, confronting risk management, complaints, and remediation services.
Similar to Requirements for Standardized Study Data: Update on Guidance (20)
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
- Video recording of this lecture in English language: https://youtu.be/RvdYsTzgQq8
- Video recording of this lecture in Arabic language: https://youtu.be/ECILGWtgZko
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
This presentation gives information on the pharmacology of Prostaglandins, Thromboxanes and Leukotrienes i.e. Eicosanoids. Eicosanoids are signaling molecules derived from polyunsaturated fatty acids like arachidonic acid. They are involved in complex control over inflammation, immunity, and the central nervous system. Eicosanoids are synthesized through the enzymatic oxidation of fatty acids by cyclooxygenase and lipoxygenase enzymes. They have short half-lives and act locally through autocrine and paracrine signaling.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
Congestive Heart failure is caused by low cardiac output and high sympathetic discharge. Diuretics reduce preload, ACE inhibitors lower afterload, beta blockers reduce sympathetic activity, and digitalis has inotropic effects. Newer medications target vasodilation and myosin activation to improve heart efficiency while lowering energy requirements. Combination therapy, following an assessment of cardiac function and volume status, is the most effective strategy to heart failure care.
Pharmacology of Drugs for Congestive Heart Failure
Requirements for Standardized Study Data: Update on Guidance
1. Requirements for Standardized Study Data:
Update on Guidance
Ron Fitzmartin, PhD, MBA
Data Standards Program
Office of Strategic Programs
Center for Drug Evaluation & Research
Food and Drug Administration
Presented at the
CSS / PhUSE Meeting
Silver Spring, MD
17 March 2014
2. 2
Disclaimer
The views and opinions presented here represent
those of the speaker and should not be considered
to represent advice or guidance on behalf of the
Food and Drug Administration.
4. 4
Road to Required Electronic Standardized
Study Data
5.
6. 6
…no earlier than 24
months after final
guidance issued after
public notice”
[certain] submissions
shall be submitted in
such electronic
format as specified
by the Secretary in
such guidance.
… the [FDA] may—provide
a timetable for
establishment
of further standards for
electronic submission as
required and set forth
criteria for waivers of and
exemptions
from the requirements.
FDASIA Statute*
Authorized Required Electronic Submissions
CDER
CBER
*FDASIA: FDA Safety & Innovation Act (2012)
7. FDASIA* Re-Authorized PDUFA V
PDUFA V
Goals –Section
XII
7
“…develop
standardized clinical
data terminology
through open
standards
development
organizations (i.e.,
CDISC)”
“… periodically publish
final guidance specifying
the completed data
standards, formats, and
terminologies that
sponsors must use to
submit data in
applications.”
*FDASIA: FDA Safety & Innovation Act (2012)
8. Re-Designed FDA Web Page
8
Quick access to
Catalog, Guidance
and Tech Guide
http://www.fda.gov/forindustry/datastandards/studydatastandards/default.htm
9. Draft Binding Guidances & Tech Guide
Published for Public Comment: 6 February 2014
http://www.fda.gov/forindustry/datastandards/studydatastandards/default.htm 9
10. What is Binding Guidance?
10
Guidance =
Binding
Guidance =
“Please”
• Recommends,
• Suggests,
• Encourages
• Requires
Do it!
Binding
Guidance
has a bite!
11. • Submission types:
– NDAs, ANDAs, Certain BLAs & INDs
• Submission not in the electronic
format(s) specified in guidance will
not be filed.
• Electronic submissions are required
no earlier than 24 months after a
final guidance is issued.
• Individual draft guidances will be
developed.
11
FDASIA 745A(a) Guidance (1)
12. • Electronic submission of
standardized study data
required for:
– Certain INDs
– NDAs
– ANDAs
– Certain BLAs
• Including amendments,
supplements, and reports
12
eStudy Data Guidance (1)
13. • Study data must be submitted
electronically or it will not be
filed…unless exempt:
– Devices regulated by CBER as
biological products under Section 351
of the PHS Act
– Study data in noncommercial INDs
(e.g., investigator-sponsored INDs,
emergency use INDs, and treatment
INDs).
13
eStudy Data Guidance (2)
14. • What are the requirements for
Standardized Study Data?
– Must be in a format that FDA can
process, review, and archive.
– Formats listed in the Data Standards
Catalog (DSC).
– DSC lists the supported and/or required
standards.
– DSC lists key dates for each standard.
14
eStudy Data Guidance (3)
http://www.fda.gov/forindustry/datastandards/studydatastandards/default.htm
15. • What are the requirements for
Standardized Study Data?
– DSC lists (or will) dates when:
• Support begins and ends
• Requirement begins and ends
• FDA may Refuse To File
– If study data do not conform to the
required standards, formats, and
terminologies.
15
eStudy Data Guidance (4)
http://www.fda.gov/forindustry/datastandards/studydatastandards/default.htm
17. • Will there be waivers from the
requirement?
– No.
– However, waivers may be granted to
use specific (e.g., retired) versions of
standards listed in the Data Catalog.
17
eStudy Data Guidance (6)
18. • Initial Timetable for Requirements
– NDAs, ANDAs, certain BLA Submissions
• Studies that start 24 months after publication of final
eStudy Guidance.
– Start Date defined as by CDISC SDTM Trial Summary
Domain
• Studies must use the standards, formats,
terminologies posted in Data Standards Catalog.
– Certain IND Submissions
• Studies that start 36 months after publication of final
eStudy Guidance.
18
eStudy Data Guidance (7)
19. • Initial Timetable for Requirement – Example
– November 15, 2014 - Federal Register Notice of final
eStudy Guidance
• #1- Sponsor starts a study October 22, 2016
– Submission of Standardized Study Data not required (but
recommended) for that study.
• #2- Sponsor starts a study December 3, 2016
– Submission of Standardized Study Data will be required
for that study.
– Must use FDA-supported standards, formats and
terminologies specified in the Data Standards Catalog.
19
eStudy Data Guidance (8)
20. • Version Updates
– Types
• Content or structural changes (e.g., new SDTM
domains or variables).
• Typographical errors, corrections, or clarifications.
– Federal Register notice will specify the effective date
and will correspond to a specific calendar month, e.g.,
March.
– Required in submissions for studies starting no earlier
than 12 months after the Federal Register notice.
20
eStudy Data Guidance (9)
21. • Version Updates – Example
– May 6, 2016, Federal Register notice - support for
new version, SDTM 4.1, and update to the Data
Standards Catalog.
• Effective date posted in the Federal Register notice is
March 15, 2017.
• Required in submissions for studies that start after
March 15, 2018.
• The Data Standards Catalog will list March 15, 2018 as
the “date requirement begins.”
21
eStudy Data Guidance (10)
22. • New Standards
– New standards, formats and terminologies
• Not supported by FDA and
• Not listed in the Data Standards Catalog when Guidance
is final.
– After notice in the Federal Register, required in
submissions for studies that start
• 24 months (NDAs, ANDAs, and certain BLAs) and
• 36 months (for certain INDs).
22
eStudy Data Guidance (11)
24. Study Data Tech Conformance Guide
• Guide supplements the eStudy
guidance.
• Provides technical recommendations /
specs for e submission of
standardized data in INDs, NDAs,
ANDAs, and BLAs.
• Consolidates Common Issues and
Study Data Specs + much more.
http://www.fda.gov/forindustry/datastandards/studydatastandards/default.htm 24
25. Study Data Tech Conformance Guide
http://www.fda.gov/forindustry/datastandards/studydatastandards/default.htm 25
26. Next Steps
• eGuidances
– Public Comment Period ends May 7th.
– Revise draft documents.
– Publish final documents in FY2015.
• Other Activities
– XML Transport Pilot for study data
– Testing & Acceptance project for data standards
– TA project plan update in FY2014
– TA development – internal and CFAST ongoing
26